This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.
Dana Rathkopf, MD
Advertisement
Articles by Dana Rathkopf, MD
Advertisement
Latest Updated Articles
Expanding Androgen- and Androgen Receptor Signaling–Directed Therapies for Castration-Resistant Prostate CancerPublished: August 15th 2014 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
3
3 Things You Should Know About Single-Agent ADCs in TNBC Treatment
4
ZEN-3694 Earns FDA Orphan Drug Designation in NUT Carcinoma
5
